Such CD47-blocking mAbs were shown to be effective by allowing the decrease of tumor burden in several preclinical cancer models including acute myeloid leukemia (Majeti et al., 2009), lymphoma (Chao et al., 2010) and osteosarcoma (Xu et al., 2015). Here, CD47 is linked to cancer.